Kilitch Drugs (India) Ltd (KILITCH) is currently trading at 203.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kilitch Drugs (India) Limited is a vertically integrated pharmaceutical formulations company manufacturing and marketing a broad range of dosage forms—including solids, liquids and parenterals—serving domestic and export markets with both OTC and ethical prescription portfolios and operating manufacturing facilities in Thane and a newly set up plant at Pen in 2026. Standalone Q1 FY2026-27 total income was Rs. 4,445.96 lakhs with net sales of Rs. 4,091.20 lakhs, showing roughly 20% year-on-year revenue growth versus Q1 last year; standalone PBT of Rs. 694.80 lakhs and PAT of Rs. 505.24 lakhs indicate healthy operational profitability before consolidation adjustments. Consolidated results differ materially from standalone performance: consolidated total income of Rs. 4,777.58 lakhs delivered a lower consolidated PAT of Rs. 196.74 lakhs for the quarter, reflecting subsidiary losses, higher finance costs and consolidation adjustments that compress group margins relative to the standalone entity. Other income and a sizeable positive other comprehensive income item supported total comprehensive income, lifting standalone comprehensive result to Rs. 1,005.46 lakhs for the quarter; this suggests non-operating items and fair value/translation gains materially influenced reported quarterly outcomes.

Over the past 52 weeks, Kilitch Drugs (India) Ltd has traded between a low of ₹117.25 and a high of ₹267.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kilitch Drugs (India) Ltd has a market capitalization of approximately 711.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kilitch Drugs (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.36 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 711.47 Cr, Kilitch Drugs (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kilitch Drugs (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kilitch Drugs (India) Ltd is 24.36. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.